Skip to main content
. Author manuscript; available in PMC: 2011 Sep 9.
Published in final edited form as: Aliment Pharmacol Ther. 2008 Jan 29;27(8):697–712. doi: 10.1111/j.1365-2036.2008.03632.x

Figure 4.

Figure 4

Impact of adherence on the effectiveness and cost-effectiveness of F-DNA version 1.1 compared with FOBT. F-DNA version 1.1 became more effective than FOBT when the per-cycle adherence with FOBT fell below 85%, and it cost an incremental $50,000/life-year gained when the per-cycle adherence with FOBT was 31%.